Compare PLX & SEVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLX | SEVN |
|---|---|---|
| Founded | 1993 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.0M | 191.2M |
| IPO Year | 1996 | 2008 |
| Metric | PLX | SEVN |
|---|---|---|
| Price | $2.85 | $8.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $12.00 | $11.50 |
| AVG Volume (30 Days) | ★ 1.1M | 91.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 13.24% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.00 |
| Revenue | ★ $53,399,000.00 | $29,383,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $23.86 | $4.06 |
| P/E Ratio | ★ N/A | $8.46 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.34 | $8.23 |
| 52 Week High | $3.19 | $13.02 |
| Indicator | PLX | SEVN |
|---|---|---|
| Relative Strength Index (RSI) | 53.49 | 43.30 |
| Support Level | $2.59 | $8.33 |
| Resistance Level | $3.03 | $8.95 |
| Average True Range (ATR) | 0.13 | 0.16 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 60.87 | 34.85 |
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in originating and investing in floating-rate first mortgage loans secured by middle-market and transitional commercial real estate. Its primary objective is to balance capital preservation with the generation of risk-adjusted returns. The company operates in one business segment: originating and investing in floating-rate first mortgage loans secured by CRE properties.